TLX having yet another go at that 4.70/4.80 resistance zone.
MSB continuing to benefit from that highly controversial FDA Alzheimer drug approval earlier in the week. Possibly with the thought that if the FDA approved that, it gives MSB a better chance of getting approvals in the future. Now at $2.14 after having spent a lot of time under $2 recently.
